$2.03
-0.05 (-2.40%)
Open$2.09
Previous Close$2.08
Day High$2.10
Day Low$2.00
52W High$7.61
52W Low$1.79
Volume—
Avg Volume632.9K
Market Cap111.05M
P/E Ratio—
EPS$-0.98
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,328.1% upside
Current
$2.03
$2.03
Target
$28.99
$28.99
$18.54
$28.99 avg
$38.99
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 26.85M | 22.92M | 271.86M |
| Net Income | -64,524,193 | -49,574,674 | 13.33M |
| Profit Margin | -240.3% | -228.3% | 4.9% |
| EBITDA | -72,144,557 | -58,508,903 | 20.13M |
| Free Cash Flow | — | — | 11.27M |
| Rev Growth | +17.1% | +17.1% | -6.6% |
| Debt/Equity | — | — | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |